Last reviewed · How we verify
NCT04106167
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
trial testing Allogeneic natural killer (NK) cell in Advanced Solid Tumor in 20 participants. Terminated before completion.
11 August 2023
Quick facts
| Lead sponsor | Fate Therapeutics |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 11 June 2019 |
| Primary completion | 11 August 2023 |
| Estimated completion | 11 August 2023 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Allogeneic natural killer (NK) cell
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
- Lymphoma — all drugs for Lymphoma →
- Gastric Cancer — all drugs for Gastric Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Fate Therapeutics — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumor or Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Exploring the NK cell platform for cancer immunotherapy.
Myers JA, Miller JS. · · 2021 · cited 977× · PMID 32934330 · DOI 10.1038/s41571-020-0426-7 -
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038 -
Emerging immunotherapy for HCC: A guide for hepatologists.
Foerster F, Gairing SJ, Ilyas SI, Galle PR. · · 2022 · cited 185× · PMID 35253934 · DOI 10.1002/hep.32447 -
Inflammatory Mechanisms of HCC Development.
Refolo MG, Messa C, Guerra V, Carr BI, et al · · 2020 · cited 149× · PMID 32164265 · DOI 10.3390/cancers12030641 -
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.
Blazar BR, Hill GR, Murphy WJ. · · 2020 · cited 97× · PMID 32313224 · DOI 10.1038/s41571-020-0356-4 -
The role of natural killer cell in gastrointestinal cancer: killer or helper.
Wang F, Lau JKC, Yu J. · · 2021 · cited 66× · PMID 33262461 · DOI 10.1038/s41388-020-01561-z -
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies.
Shankar K, Capitini CM, Saha K. · · 2020 · cited 64× · PMID 32546200 · DOI 10.1186/s13287-020-01741-4 -
Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches.
Mantovani S, Oliviero B, Varchetta S, Mele D, et al · · 2020 · cited 55× · PMID 32283827 · DOI 10.3390/cancers12040926
Verify or expand the search:
- PubMed search for NCT04106167
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other Fate Therapeutics trials
Trials by the same sponsor.
- NCT06308978 — A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease · Phase 1 · recruiting
- NCT06241456 — FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors · Phase 1 · recruiting
- NCT05950334 — FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) · Phase 1 · completed
- NCT05395052 — FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors · Phase 1 · terminated
- NCT05182073 — FT576 in Subjects With Multiple Myeloma · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04106167 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fate Therapeutics
- Last refreshed: 21 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04106167.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing